The fight against the COVID-19 pandemic continues and another significant milestone has been achieved. Joining the three COVID-19 vaccines that have already been approved by the European Medicines Agency is the one produced by Johnson and Johnson. This vaccine will be the fourth to be used amongst the twenty-seven member states.
The vaccine produced by Johnson and Johnson is administered via a single dose. This alleviates the pressure on human resources, as more people can achieve immunity quicker. The latest approval is expected to boost the European Union’s efforts in its vaccination programme, which till now leaves a lot to be desired. In a statement by the company, it is believed that the first doses of the vaccine will be supplied to the European Union, Norway and Iceland, in April. During the course of 2021, the company is expected to deliver two hundred million doses to European Union countries, with an option of two hundred million more.
The European Union Commission President Ursula von der Leyen had an optimistic message to share, stating that safe and effective vaccines are available.
Apart from the fact that this will be the first COVID-19 vaccine to be administered through a single dose, it is also easier to store. Another three vaccines are currently being reviewed by the European Medicines Agency. These are Novavax, CureVac and Sputnik V.
The clinical trials for the Johnson and Johnson vaccine took place in the United States, South Africa and South American countries. The company proved that the vaccine yielded satisfactory levels of effectiveness. It was found that the Johnson and Johnson vaccine was eighty-five percent effective in preventing severe COVID-19 and a hundred percent at preventing death. In the United States, the single dose was seventy-two percent effective at preventing moderate to severe disease.
The side-effects of the vaccines were described to be either mild or moderate. These would typically include pain in the area where the injection was administered, headache, tiredness, muscle pain and nausea.
Whilst the Johnson and Johnson vaccine provides several benefits for the campaign against COVID-19, it appears to be less protective than the Pfizer and Moderna vaccines, which are dubbed to be in the region of ninety-five percent effectiveness against all forms of COVID-19.
The Johnson and Johnson vaccine comes at a time where the European Union is struggling due to a shortage of doses.
What are your views about the latest addition of the Johnson and Johnson vaccine? Let us know your views in the comments section below.